Epstein-Barr Virus Related Carcinoma, Nasopharyngeal Cancer
Conditions
Keywords
Somatostatin, EBV, NPC, Rare Cancer
Brief summary
The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.
Interventions
RADIATIONFDG-PET
Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
RADIATIONGalium-68 DOTATATE
200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
Sponsors
National Cancer Centre Research Fund
National Cancer Centre, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations * Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging * Histologically confirmed NPC * Above 21 years of age
Exclusion criteria
* Patients below 21 years of age * Pregnant and breast feeding ladies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amount of tracer uptake in the tumour lesions of NPC patients | From time of tracer injection to time the scan is performed | The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of tracer uptake in the tumour lesions of patients with EBV related cancers | From time of tracer injection to time the scan is performed | The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density. |
| Number of somatostatin receptors in patient biopsy samples | Upon signing the informed consent form | — |
| Amount of somatostatin circulating tumour cells in patient blood samples | At the time of scan | — |
Countries
Singapore
Outcome results
None listed